TICKERNERD
Menu
MDMDHealthcare · Medical Care Facilities

MD Stock Forecast: Pediatrix Medical Group, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$33
+7.19% on the day

The 7 Wall Street analysts covering Pediatrix Medical Group, Inc. hold a median 12-month price target of $29 — -11.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 3 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$2.4B
Ticker Nerd rank
100/ 100
Median analyst target
$29
Analysts covering
7
Revenue$487.8M+4.0% y/y
Operating income$65.4M
Net income$39.8M
Free cash flow$123.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+13.5%
1M
+26.3%
YTD
+53.3%
1Y
+53.0%
From 52W high
0.0%
From 52W low
+74.3%
$19
$33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pediatrix Medical Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
100/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Issuance
96
Value
95
Revisions
93
Volatility
92
Quality
90
Accruals
72
Growth
44
Size
32

Momentum (98): The shares have been drifting up relative to others.

Growth (44): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (32): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30Jan 26Apr 26Jul 26Oct 26MDHigh $31Median $29Low $28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
1 Buy6 Hold0 Sell
Low $28Median $29High $31

The green dot is the last close — the median target sits −11.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 Oct 2026Truist SecuritiesMaintainsHold$28 → $31
19 Aug 2026JefferiesDowngradeHold—
19 Aug 2026JefferiesDowngradeHold$27 → $28
6 Aug 2026UBSMaintainsNeutral$25 → $28
6 Aug 2026UBSMaintainsNeutral—
14 July 2026Truist SecuritiesMaintainsHold$23 → $28
14 July 2026Truist SecuritiesMaintainsHold—
12 May 2026UBSMaintainsNeutral—
13 Apr 2026Truist SecuritiesMaintainsHold—
24 Feb 2026UBSMaintainsNeutral—
20 Feb 2026Truist SecuritiesMaintainsHold—
10 Nov 2025Truist SecuritiesMaintainsHold—
5 Nov 2025UBSMaintainsNeutral—
5 Sept 2025Leerink PartnersMaintainsMarket Perform—
14 Aug 2025UBSMaintainsNeutral—
12 May 2025UBSMaintainsNeutral—
8 May 2025MacquarieMaintainsOutperform—
11 Apr 2025Truist SecuritiesMaintainsHold—
21 Feb 2025Truist SecuritiesMaintainsHold—
21 Feb 2025UBSMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Pediatrix Medical Group, Inc. returned +53.0% against +14.8% for the S&P 500, dividends included.

MD vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26MDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+4.8%
Analysts raising
5
Analysts cutting
0
Fundamentals

Pediatrix Medical Group, Inc. (MD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
16.8×

Cheaper than 42% of US stocks

Price / sales
1.2×

Cheaper than 64% of US stocks

Price / book
2.7×

Cheaper than 33% of US stocks

EV / EBITDA
9.6×

Cheaper than 39% of US stocks

Growth & margins
Revenue growth (YoY)
1.7%

Higher than 31% of US stocks

Earnings growth (YoY)
−34.5%

Higher than 15% of US stocks

Gross margin
27.2%

Higher than 30% of US stocks

Operating margin
14.2%

Higher than 71% of US stocks

Net margin
7.7%

Higher than 65% of US stocks

Returns & dividend
Return on equity
17.2%

Higher than 78% of US stocks

Return on assets
6.9%

Higher than 84% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pediatrix Medical Group, Inc. (MD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pediatrix Medical Group, Inc. has a market value of $2.4B and an enterprise value of $2.5B.

  • Revenue in the twelve months to 30 June 2026: $2.0B. The latest quarter grew 1.7% year on year.

  • Net income over the same four quarters: $174.8M, a 9.0% net margin.

  • Diluted earnings per share, trailing twelve months: $2.09.

  • Free cash flow in the twelve months to 30 June 2026: $228.6M.

  • Pediatrix Medical Group, Inc. spent $149.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 81.2M.

  • Trailing P/E: 16.8×; forward P/E: 12.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Pediatrix Medical Group, Inc. employs 4,280 people — $456K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

MD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
MDPediatrix Medical Group, Inc.$2.4B100
BKDBrookdale Senior Living, Inc.$2.5B66
GRDNGuardian Pharmacy Services, Inc.$2.6B77
ADUSAddus HomeCare Corp.$2.4B95
ACHCAcadia Healthcare Co., Inc.$2.7B51
AVAHAveanna Healthcare Holdings, Inc.$2.9B87
SGRYSurgery Partners, Inc.$3.0B41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pediatrix Medical Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MD news & analysis

What Pediatrix Medical Group (MD) Said on Its Q3 Earnings Call

MarketBeat · 30 Oct 2026positive

Pediatrix Medical Group reported third-quarter 2026 adjusted EBITDA of $85 million, saying results exceeded management’s expectations despite rising healthcare delivery costs. It narrowed its full-year adjusted EBITDA outlook to $290 million–$300 million.

Why it matters — The results and revised outlook provide MD watchers with an update on operating performance and management’s expectations for the full year.

Pediatrix Medical Group, Inc. (MD) Q3 2026 Earnings Call Transcript

Seeking Alpha · 29 Oct 2026neutral

Pediatrix Medical Group held its Q3 2026 earnings call on October 29, 2026, with company executives and analysts participating. The excerpt provides the call details but no financial results or management commentary.

Why it matters — MD watchers may note the earnings-call date and participants, but the excerpt contains no substantive update on the company’s performance.

Pediatrix Medical Group (MD) Beats Q3 Earnings and Revenue Estimates

Zacks Investment Research · 29 Oct 2026positive

Pediatrix Medical Group reported quarterly earnings of $0.72 per share, above the Zacks Consensus Estimate of $0.63. Earnings were $0.67 per share a year earlier.

Why it matters — The results provide MD watchers with an update on quarterly earnings relative to analyst estimates and the prior-year quarter.

Pediatrix Medical Group Reports Third Quarter Results

Business Wire · 29 Oct 2026neutral

Pediatrix Medical Group reported its third-quarter results, according to a Business Wire headline.

Why it matters — The item concerns Pediatrix’s quarterly results, which are relevant to investors following MD.

FAQ

Frequently asked questions about MD stock

What is the MD stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Pediatrix Medical Group, Inc. have a median 12-month price target of $29, with estimates ranging from $28 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MD stock a buy right now?

Of the 7 analysts covering Pediatrix Medical Group, Inc., 1 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pediatrix Medical Group, Inc. 100 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MD?

As at 3 Nov 2026, Pediatrix Medical Group, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will MD stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies -11.6% from the last close, and Ticker Nerd's factor model ranks Pediatrix Medical Group, Inc. 100 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MD stock forecast for 2030?

No analyst covering Pediatrix Medical Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $31 over the next 12 months.

How has MD stock performed over the past year?

Pediatrix Medical Group, Inc. returned +53.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pediatrix Medical Group, Inc. do?

Pediatrix Medical Group Inc. is a physician services company focused on newborn, maternal-fetal, and pediatric subspecialty care.

What is the latest news on MD?

The most recent item we track (MarketBeat, 30 Oct 2026): "What Pediatrix Medical Group (MD) Said on Its Q3 Earnings Call". Pediatrix Medical Group reported third-quarter 2026 adjusted EBITDA of $85 million, saying results exceeded management’s expectations despite rising healthcare delivery costs. It narrowed its full-year adjusted EBITDA outlook to $290 million–$300 million.

Company

About Pediatrix Medical Group, Inc.

Pediatrix Medical Group Inc. is a physician services company focused on newborn, maternal-fetal, and pediatric subspecialty care. It provides hospital-based and office-based clinical services for premature and medically complex infants, expectant mothers, and children requiring specialized treatment. The company’s care network includes neonatologists, maternal-fetal medicine specialists, pediatric subspecialists, nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. Pediatrix Medical Group also supports hospitals and health systems with clinical staffing and related physician-led service lines across neonatal intensive care, women’s health, pediatric cardiology, pediatric critical care, pediatric emergency medicine, and anesthesia care. Headquartered in Sunrise, Florida, Pediatrix Medical Group plays an important role in delivering specialized care in high-acuity settings where coordinated expertise and continuity of treatment are essential.

CEO Mr. Mark S. Ordan · 4,280 employees · United States · https://www.pediatrix.com